Cervical cancer screening

被引：13

作者：

Wiley D.J. ^{[1
]}

Monk B.J. ^{[1
]}

Masongsong E. ^{[1
]}

Morgan K. ^{[1
]}

机构：

[1] Division of Primary Care, School of Nursing, University of California, Los Angeles

来源：

Current Oncology Reports | 2004年 / 6卷 / 6期

关键词：

Cervical Cancer; Cervical Intraepithelial Neoplasia; Cervical Cancer Screening; Invasive Cervical Cancer; Cervical Cytology;

D O I：

10.1007/s11912-004-0083-5

中图分类号：

学科分类号：

摘要：

Although primary prevention of human papillomavirus (HPV) infections that are causally associated with invasive cervical cancer may be within our grasp, it is unlikely that these approaches will replace existing cervical cancer screening strategies for many years. Experts agree and data support periodic cytology screening for young-adult women using one of several technologies. Recent analyses of cost-effectiveness suggest that the addition of molecular HPV DNA testing for women aged over 30 years may allow the screening interval to be lengthened to 3 years for most women. Women at high risk for HPV infection and its associated cellular atypias warrant closer monitoring and follow-up. These patients would include organ transplant recipients, women exposed to diethylstilbestrol (DES), and HIV-infected women. Copyright © 2004 by Current Science Inc.

引用

页码：497 / 506

页数：9

共 111 条

[21]

Stenkvist B., Bergstrom R., Eklund G., Fox C.H., Papanicolaou smear screening and cervical cancer. What can you expect?, JAMA, 252, pp. 1423-1426, (1984)

[22]

Paintsil J., Muller M., Picken M., Et al., Carboxyl terminus of bovine papillomavirus type-1 L1 protein is not required for capsid formation, Virology, 223, pp. 238-244, (1996)

[23]

Koutsky L.A., Ault K.A., Wheeler C.M., Et al., A controlled trial of a human papillomavirus type 16 vaccine, N. Engl. J. Med., 347, pp. 1645-1651, (2002)

[24]

Christensen N.D., Kirnbauer R., Schiller J.T., Et al., Human papillomavirus type-6 and type-11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes, Virology, 205, pp. 329-335, (1994)

[25]

Strickler H.D., Schiffman M.H., Shah K.V., Et al., A survey of human papillomavirus 16 antibodies in patients with epithelial cancers, Eur. J. Cancer Prev., 7, pp. 305-313, (1998)

[26]

Sun Y., Eluf-Neto J., Bosch F.X., Et al., Serum antibodies to human papillomavirus 16 proteins in women from Brazil with invasive cervical carcinoma, Cancer Epidemiol. Biomarkers Prev., 8, pp. 935-940, (1999)

[27]

Combita A.L., Bravo M.M., Touze A., Et al., Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in Colombian women with invasive cervical cancer, Int. J. Cancer, 97, pp. 796-803, (2002)

[28]

Goldstone S.E., Palefsky J.M., Winnett M.T., Neefe J.R., Activity of HspE7, a novel immunotherapy, in patients with anogenital warts, Dis. Colon Rectum, 45, pp. 502-507, (2002)

[29]

Chu N.R., Wu H.B., Wu T.C., Et al., Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7, Cell Stress Chaperones, 5, pp. 401-405, (2000)

[30]

Chu N.R., Wu H.B., Wu T., Et al., Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7, Clin. Exp. Immunol., 121, pp. 216-225, (2000)

← 1 2 3 4 5 6 7 8 9 10 →